MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bjh.19182

Медицинская библиотека · British journal of haematology · 2023

Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.

Chen Nianci, Pan Jiajia, Zhou Yile, Mao Liping, Lou Yinjun, Qian Jiejing, Xu Gaixiang, Wei Juying, Zhou De, Shou Lihong, Huang Li, Yan Minchao, Zeng Hui, Fan Cuihua, Wu Gongqiang, Feng Weiying, Tong Hongyan, Jin Jie, Wang Huafeng

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Gilteritinib, a potent FMS-like tyrosine kinase 3 (FLT3) inhibitor, was approved for relapsed/refractory (R/R) FLT3-mutated acute myeloid leukaemia (AML) patients but still showed limited efficacy. Here, we retrospectively analysed the efficacy and safety of different gilteritinib-based combination therapies (gilteritinib plus hypomethylating agent and venetoclax, G + HMA + VEN; gilteritinib plus HMA, G + HMA; gilteritinib plus venetoclax, G + VEN) in 33 R/R FLT3-mutated AML patients. The composite complete response (CRc) and modified CRc (mCRc) rates were 66.7% (12/18) and 88.9% (16/18) in patients received G + HMA + VEN, which was higher compared with that in G + HMA (CRc: 18.2%, 2/11; mCRc: 45.5%, 5/11) or G + VEN (CRc: 50.0%, 2/4; mCRc: 50.0%, 2/4). The median overall survival (OS) for G + HMA + VEN, G + HMA and G + VEN treatment was not reached, 160.0 days and 231.0 days. The median duration of remission (DOR) for G + HMA + VEN, G + HMA and G + VEN treatment was not reached, 82.0 days and 77.0 days. Four patients in the G + HMA + VEN group received alloHSCT after remission exhibited prolonged median DOR. The most common grade 3/4 adverse events were cytopenia, febrile neutropenia and pulmonary infection; there were no differences among the three groups. In conclusion, our data demonstrated promising response of G + HMA + VEN combination therapy in R/R FLT3-mutated AML, and it may be considered an effective therapy bridge to transplantation.

Для цитирования: Chen Nianci, Pan Jiajia, Zhou Yile, Mao Liping, Lou Yinjun, Qian Jiejing, Xu Gaixiang, Wei Juying, Zhou De, Shou Lihong, Huang Li, Yan Minchao, Zeng Hui, Fan Cuihua, Wu Gongqiang, Feng Weiying, Tong Hongyan, Jin Jie, Wang Huafeng. Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.. British journal of haematology. 2023. DOI: 10.1111/bjh.19182.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.